EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets).
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Contraception
Conditions
Contraception, Female Contraception
Trial Timeline
Aug 1, 2002 → Mar 1, 2003
NCT ID
NCT00254865About EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets).
EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets). is a phase 1 stage product being developed by Johnson & Johnson for Contraception. The current trial status is completed. This product is registered under clinical trial identifier NCT00254865. Target conditions include Contraception, Female Contraception.
What happened to similar drugs?
15 of 20 similar drugs in Contraception were approved
Approved (15) Terminated (1) Active (5)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00254865 | Phase 1 | Completed |
Competing Products
20 competing products in Contraception